FIELD: medicine.
SUBSTANCE: invention refers to the new uracil derivative 1,3-bis[5-(orto-nitrobenzyl-ethylamino)pentyl-1]-6-methyluracil described by structural formula presented below. The compound is applicable in therapy of Alzheimer disease. 
Presented are anticholinesterase activity indices of the compound, its general toxic action and findings obtained in a scopolamine and genetic model in the therapy of symptoms of Alzheimer disease.
EFFECT: higher clinical effectiveness ensured by the above agent.
2 cl, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MACROCYCLIC ALKYLAMMONIUM DERIVATIVES OF 6-METHYLURACIL HAVING ANTICHOLINESTERASE ACTIVITY | 2013 |
|
RU2534903C1 |
| PEPTIDE FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2678987C2 |
| PHARMACEUTICAL COMPOSITION BASED ON HAEE PEPTIDE FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2709539C1 |
| PEPTIDE HAVING NEUROPROTECTIVE AND NOOTROPIC ACTIVITY AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2014 |
|
RU2557003C2 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| PHARMACEUTICALLY ACCEPTABLE ACETYL-(D-LYS)-LYS-ARG-ARG-AMIDE PEPTIDE SALTS | 2021 |
|
RU2763136C1 |
| ANTIDEPRESSANT AGENT | 2018 |
|
RU2741938C2 |
| EXOGENIC-INDUCED ANIMAL MODEL OF ALZHEIMER DISEASE | 2012 |
|
RU2532525C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING GLYCINE TRANSPORTER AS ACTIVE INGREDIENT | 2021 |
|
RU2816256C1 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
